New brand name drugs

- **Onzetra™ Xsail™ (sumatriptan, intranasal powder):** The Food and Drug Administration (FDA) approved Avanir and Optinose’s Onzetra Xsail to treat migraines, with or without an aura. The product works by blowing into the device with your mouth to deliver sumatriptan into your nose.

- **Zembrace™ SymTouch™ (sumatriptan succinate injection):** The FDA approved Dr. Reddy’s subcutaneous autoinjector to treat adults with acute migraines, with or without an aura.

- **Briviact® (brivaracetam):** UCB received FDA approval for their new drug to treat seizures. Briviact is similar to levetiracetam (Keppra®) in mechanism of action and is approved as an add-on treatment to other seizure medications to treat partial onset seizures in patients 16 and older.

New generic drugs

- **Glumetza® (metformin modified release 24hr sr):** The first generic of Valeant’s Glumetza for adults with type 2 diabetes mellitus is now available. According to IMS Health, Glumetza had approximately $450 million in annual U.S. sales.

- **Naftin® (naftifine cream, 2%):** The first generics to Merz Pharmaceuticals’ Naftin for the treatment of interdigital tinea pedis, tinea cruris, and tinea corporis have launched.